Skip to content

EBIT at other companies

AngioDynamics logo
AngioDynamicsANGO
-$12.95M-29.8%
Delcath Systems logo
Delcath SystemsDCTH
-$1.64M-355%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
-$1.53M+66.2%
LQD
Liquidia CorporationLQDA
$61.5M+274%
Boston Scientific logo
Boston ScientificBSX
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Calculated from TriSalus Life Sciences, Inc.’s reported figures.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s EBIT?
TriSalus Life Sciences, Inc. (TLSI) reported EBIT of -$8.41M in Q1 2026.
How has TriSalus Life Sciences, Inc.'s EBIT changed year-over-year?
TriSalus Life Sciences, Inc.'s EBIT decreased by 14.8% year-over-year, from -$7.33M to -$8.41M.
What is the long-term trend for TriSalus Life Sciences, Inc.'s EBIT?
Over 4 years (2021 to 2025), TriSalus Life Sciences, Inc.'s EBIT has grown at a 72.5% compound annual growth rate (CAGR), from -$3.04M to -$26.95M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.